MSB

2.51%

97.0¢ mesoblast limited

MSB Monday Opening Price, page-140

First 140 Last

Share
Profile

Follow
redbaron

2,038 Posts.

82

26/04/20

23:30

Post #: 44267943
Share

Originally posted by mja: ↑

I have analysed various studies for remestemcel, over the last few days. Of note there appear to be minimal side effects, no difference versus placebo. This cannot be understated, as "first do know harm" is a key medical axiom.

I have just reviewed another study.

Title: Factors associated with hospitalization and critical illness among 4,103 patients with
Covid-19 disease in New York City

The study ran from March 1 2020 to April 2 2020, with results compiled as at April 7 2020.

445 patients in this study received mechanical ventilation (intubated). The results were:
-16 discharged 3.6%
-162 died 36.4%
-22 extubated (off ventilation), still in hospital 4.9%
-245 still ventilated 55.1%

So 8.5% have had a good outcome, ie discharged or extubated. 36.4% have died. 55.1% are still intubated (receiving mechanical ventilation), and the longer you are ventilated the less likely you are to have a good outcome. These numbers in my opinion would be consistent with at least a 75% mortality rate. This study appears to give the best indication as to the present condition of the patients not discharged or deceased in the studies cited earlier, ie 91.8% of the inpatients (not discharged or deceased) are still being ventilated in the above study.

Remestemcel in comparison had:
-7 discharged 58.3%
-2 died 16.7%
-2 extubated, still in hospital 16.7%
-1 still ventilated 8.3%
--so 75% have had a good outcome with remestemcel, versus 8.5% in above study. The sample size is small, but the results are compelling. The other key is that the remestemcel targets the pathway that triggers ARDS, and has achieved statistically significant results in graft versus host disease post bone marrow transplant, with nil side effects of note. Graft versus host disease and ARDS can both be looked on as being autoimmune in nature ie the body inadvertently attacking itself. As opposed to we gave this medication and it seemed to help, but we are not entirely sure of the mechanism to action.

Expand

Let me know if you come across the Clinical Trial that Mesoblast is doing now for FDA approval, description and design etc...
GLA

MSB Price at posting: $2.73 Sentiment: Buy Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

BOE

Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan

VMS

Venture to sniff out high-grade REE targets at Jupiter project, WA

WGX

Westgold sets its sights on top five producer status through merger with Karora

MGU

Collaboration in a green (steel) future the focus for Magnum and Saudi partners

Week 31 Wrap: JORC rules to get tougher; RBA rate hike chance 50/50; US Fed Sept cut still the quo

GRX

GreenX picks up prospective copper project in Germany

NXG

Cost blow-out for Rook I uranium project sees share plummet for NexGen

DVP

Commodity house Trafigura funds Develop Global's copper-zinc Woodlawn play with offtake deal in place

VMT

Vmoto sales plummet -50% YoY as weak demand in Europe & China stifles EV scooter sales growth

Is oil undervalued?

There are more pages in this discussion • 173 more messages in this thread...

First 140 Last

Add MSB (ASX) to my watchlist

(20min delay)
Last 97.0¢		Change -0.025(2.51%)		Mkt cap ! $1.107B

Open	High	Low	Value	Volume
97.0¢	$1.01	96.5¢	$7.757M	7.884M

Buyers (Bids)

No.	Vol.	Price($)
10	274918	97.0¢

Sellers (Offers)

Price($)	Vol.	No.
97.5¢	974	1

View Market Depth

No.	Vol.	Price($)
6	103162	0.970
5	34741	0.965
11	125566	0.960
1	500	0.955
22	165429	0.950

Price($)	Vol.	No.
0.975	974	1
0.990	10204	1
1.000	14000	1
1.010	2877	1
1.015	60000	1

Last trade - 16.10pm 02/08/2024 (20 minute delay)

MSB (ASX) Chart

MSB Monday Opening Price, page-140

Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan

Venture to sniff out high-grade REE targets at Jupiter project, WA

Westgold sets its sights on top five producer status through merger with Karora

Collaboration in a green (steel) future the focus for Magnum and Saudi partners

Week 31 Wrap: JORC rules to get tougher; RBA rate hike chance 50/50; US Fed Sept cut still the quo

GreenX picks up prospective copper project in Germany

Cost blow-out for Rook I uranium project sees share plummet for NexGen

Commodity house Trafigura funds Develop Global's copper-zinc Woodlawn play with offtake deal in place

Vmoto sales plummet -50% YoY as weak demand in Europe & China stifles EV scooter sales growth

Is oil undervalued?

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

MSB Monday Opening Price, page-140

Top Stories

Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan

Venture to sniff out high-grade REE targets at Jupiter project, WA

Westgold sets its sights on top five producer status through merger with Karora

Collaboration in a green (steel) future the focus for Magnum and Saudi partners

Week 31 Wrap: JORC rules to get tougher; RBA rate hike chance 50/50; US Fed Sept cut still the quo

GreenX picks up prospective copper project in Germany

Cost blow-out for Rook I uranium project sees share plummet for NexGen

Commodity house Trafigura funds Develop Global's copper-zinc Woodlawn play with offtake deal in place

Vmoto sales plummet -50% YoY as weak demand in Europe & China stifles EV scooter sales growth

Is oil undervalued?

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News